Process for treating human perspiration and associated composition

FR3142343B1Active Publication Date: 2024-11-29LOREAL SA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2022012560
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2022-11-30
Publication Date
2024-11-29
Estimated Expiration
2042-11-30

AI Technical Summary

Technical Problem

Existing antiperspirant and deodorant compositions face challenges such as limited effectiveness, formulation difficulties, and skin irritation when used at high concentrations, and there is a need for a composition that is easily formulated, stable, and well-tolerated by the skin while providing a satisfactory deodorant effect.

Method used

An aqueous composition comprising magnesium chloride, dipotassium phosphate, xanthan gum, capryloyl salicylic acid, and optionally hydroxylated mono- or polycarboxylic acids, which is applied to the skin in various forms, including mixing separately or simultaneously, to treat perspiration and body odors.

Benefits of technology

The composition effectively reduces perspiration and body odors, is easy to formulate, stable, and well-tolerated by the skin, without causing irritation or staining clothing.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Method for treating human perspiration and associated composition. The present invention relates to a composition comprising, in a cosmetically acceptable aqueous medium, magnesium chloride, dipotassium phosphate, xanthan gum, capryloyl salicylic acid, and at least one modulating agent selected from mono- or polycarboxylic acids, optionally hydroxylated, in free or salified form. It also relates to the associated method. Figure for the abstract: none
Need to check novelty before this filing date? Find Prior Art

Description

Description Title of the invention: Method for treating perspiration human and associated composition

[0001] — The present invention relates to a cosmetic method for treating trans- human inhalation and possibly body odor resulting from perspiration, as well as an associated cosmetic composition.

[0002] — The armpits as well as certain other parts of the body are generally the place of several discomforts which may come directly or indirectly from the phenomena of sweating. These phenomena often lead to unpleasant sensations and annoying which are mainly due to the presence of sweat resulting from the trans- piration which can, in some cases, make the skin clammy and wet clothes, especially in the armpits or back, leaving visible marks. By elsewhere, the presence of sweat can cause the release of body odors which are mostly unpleasant. Such discomforts are to be taken into account, including including in the case of moderate sweating.

[0003] — In the cosmetic field, it is thus well known to use in topical application, deodorant products containing substances that have the effect of masking, absorb, improve and / or reduce the unpleasant odor resulting from decomposition human sweat and remedy the problems mentioned above. These products are generally available in roll-on, stick, aerosol or spray form.

[0004] There are also antiperspirant compositions on the market, which com- usually take aluminum and / or zirconium chlorohydrates. These substances help reduce the flow of sweat by forming a plug at the level of the sweat duct.

[0005] — However, the use of these substances at high concentrations for the purpose to obtain good efficiency leads to difficulties in formulation. In addition, It has been found that the antiperspirant effectiveness of these substances is limited when used alone.

[0006] — To remedy all of the drawbacks mentioned above, it has been proposed to search for other effective active substances, well tolerated by the skin and fa- clearly formulable.

[0007] — Among the recently worked approaches is the use of magnesium oxide (MgO) in various galenic forms: this active ingredient has proven its effectiveness in fragrant, but the formula still needs to be improved.

[0008] — Another axis is that described in WO2019 / 072831: this application describes a method cosmetic treatment of human perspiration and possibly cor- odors pores resulting from perspiration, which includes the use of at least one cation X "+ of valence n, at least one anion Y of valence m and at least one modulating agent. However, not all the cations and anions described are equivalent, and the galenics needed to be improved. There is therefore a real need to implement on the skin an agent intended for the treatment of human perspiration which does not have all of the disadvantages described above, that is to say which provides a satisfactory deodorant effect, and which is well tolerated by the skin. In addition, there is a need for such a deodorant agent intended for the treatment of human perspiration, which is easily formulable, non-irritating, and which is stable during storage. The Applicant surprisingly discovered that this objective could be achieved with an aqueous composition comprising magnesium chloride (MgCl;), dipotassium phosphate (K,HPO;), xanthan gum and capryloyl salicylic acid. The resulting composition is easy to formulate, stable, and has deodorant efficacy. The present invention therefore relates to a composition comprising, in a cosmetically acceptable aqueous medium, magnesium chloride (MgCl.), dipotassium phosphate (K,HPO;), xanthan gum, caprylyl salicylic acid and at least one modulating agent chosen from optionally hydroxylated mono- or polycarboxylic acids, in free or salified form. By 'cosmetically acceptable aqueous medium' is meant an aqueous medium compatible with the skin and / or its appendages or mucous membranes which has a pleasant color, odor and feel and which does not generate discomfort (such as tightness) likely to discourage the consumer from using this composition. The said cosmetically acceptable medium is also a medium which does not leave traces when applied, and therefore does not stain clothing. Said cosmetically acceptable medium is aqueous, i.e. comprises an aqueous phase. The present invention also relates to a cosmetic process for treating human perspiration and possibly body odors resulting from perspiration (hereinafter “process according to the invention”), comprising the application of a composition according to the invention to the skin. The present invention finally relates to a cosmetic process for treating human perspiration and possibly body odors resulting from perspiration (hereinafter “process 2 according to the invention”), which comprises: (i) either the mixing just before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately followed by the application of the resulting mixture to the surface of the skin; (ii) either the application to the surface of the skin simultaneously or sequentially of at least one composition A and at least one composition B packaged separately; (iii) either the application to the surface of the skin of a composition comprising in the same support at least one composition A and at least one composition B; said composition comprising in a cosmetically ac- aqueous medium acceptable at least magnesium chloride (MgCl»); said composition B comprising in a cosmetically ac- aqueous medium acceptable at least dipotassium phosphate (K,HPO4); said composition A and / or said composition B comprising gum xanthan; said composition A and / or said composition B comprising acid capryloyl salicylic acid; and said composition A and / or said composition B also comprising at at least one modulating agent chosen from mono- or polycar- acids carboxylic, possibly hydroxylated, in free or salified form. By "sequential" we mean successive administration. By "same support" is meant that compositions A and B according to the invention are present in the same packaging, in particular a two-compartment packaging which allows the simultaneous application of compositions A and B. Composition The composition according to the invention comprises, in a cosmetically acceptable aqueous medium, magnesium chloride (MgCl2), dipotassium phosphate (K,;HPO; ), xanthan gum, caprylyl salicylic acid and at least one modulating agent chosen from mono- or polycarboxylic acids, optionally hydroxylated, in free or salified form. AQUEOUS PHASE The composition comprises an aqueous phase (also called a cosmetically acceptable aqueous medium). It is notably formulated as an aqueous gel. The aqueous phase of the composition contains water and generally other water-soluble or miscible solvents. Water-soluble or miscible solvents include short-chain monoalcohols, for example C, -C, such as ethanol, isopropanol; diols or polyols such as ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2-ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether and sorbitol, preferably 1,2-propylene glycol. Preferably, the composition comprises from 1% to 30% by weight of solvent(s). soluble or miscible in water relative to the total weight of composition, preferably from 2% to 25% by weight, preferably from 4% to 22% by weight. Preferably, the composition comprises at least 50% by weight of water relative to the total weight of the composition, preferably at least 55% by weight, preferably at least 70% by weight. Preferably, the composition comprises from 50% to 90% by weight of water relative to the total weight of the composition, preferably from 55% to 85% by weight, preferably from 55% to 80% by weight. Magnesium chloride (MgCl2) Magnesium chloride (MgCl) is a water-soluble salt. For the purposes of the present invention, the term "water-soluble salt" means any salt which, after being completely dissolved with stirring at 0.5% in a water solution at a temperature of 25°C, results in a solution comprising an amount of insoluble salt of less than 0.05% by weight. Magnesium chloride (MgCl) includes in particular the cation Mg*. The composition according to the invention comprises an aqueous phase and preferably has a pH of between 2 and 6, preferably between 4 and 6. If necessary, the pH is adjusted with a cosmetically acceptable acid or base, organic or mineral. Such an acid and such a base are those conventionally used in cosmetics. Preferably, the composition comprises magnesium chloride in a content of between 1 and 30% by weight relative to the total weight of the composition, preferably between 3 and 25% by weight, preferably between 5 and 20% by weight. Dipotassium phosphate (K2HPO4) The composition according to the invention also comprises dipotassium phosphate (K,HPO;). This dipotassium phosphate (K,HPO;) is also a water-soluble salt. Dipotassium phosphate (K,HPO,) comprises in particular the anion HPO,2. Preferably, the composition comprises dipotassium phosphate (K:HPO4) in a content of between | and 25% by weight relative to the total weight of the composition, preferably between 3 and 20% by weight, preferably between 5 and 15% by weight. The weight ratio between magnesium chloride and dipotassium phosphate preferably varies from 3:1 to 1:1, preferably from 2:1 to 1:1, and more preferably from 1.5:1 to 1:1. The total concentration of magnesium chloride and dipotassium phosphate preferably varies from 7 to 40% by weight, preferably between 10 and 30% by weight, and more preferably from 15 to 25% by weight relative to the total weight of the composition. Modulating agent The composition according to the invention comprises at least one modulating agent chosen among the mono- or polycarboxylic acids, possibly hydroxylated, in free or salified form. Preferably, the polycarboxylic acids are selected from di- and tricarboxylic acids, optionally hydroxylated. Such hydroxylated carboxylic acids are also called hydroxy acids. Preferably, the modulating agent is chosen from propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid and mixtures thereof, in free or salified form. Preferably, the modulating agent is chosen from tricarboxylic acids, optionally hydroxylated, preferably from hydroxylated tricarboxylic acids. The optionally hydroxylated mono- or polycarboxylic acids are present in the composition in free form or in salified form. When present in salified form, they may be present as an alkali metal or alkaline earth metal salt, preferably as a sodium or potassium salt. Preferably, the modulating agent is a mixture of an optionally hydroxylated tricarboxylic acid in free form and an optionally hydroxylated tricarboxylic acid in salified form. Preferably, the modulating agent is a mixture of a hydroxylated tricarboxylic acid in free form and a hydroxylated tricarboxylic acid in salified form. Preferably, the modulating agent is a mixture of citric acid and sodium citrate. Preferably, the modulating agent is present in the composition in a content of between 0.1 and 10% by weight relative to the total weight of the composition, preferably between 0.5 and 5% by weight, preferably between 1 and 4% by weight. Xanthan gum The composition according to the invention comprises xanthan gum. Preferably, the xanthan gum is present in the composition in a content of between 0.1 and 7% by weight relative to the total weight of the composition, preferably between 0.5 and 5% by weight, preferably between 0.8 and 2% by weight. Deodorant active ingredient The composition according to the invention comprises capryloyl salicylic acid (also called 2-hydroxy-5-({1-oxooctyl)benzoic acid). This compound is a deodorant active ingredient. In the context of the present invention, the term "deodorant active ingredient" means any active ingredient which, on its own, has the effect of masking, absorbing, improving and / or reducing the unpleasant odor resulting from the decomposition of human sweat. Preferably, capryloyl salicylic acid is present in the composition in a content of between 0.05 and 5% by weight relative to the total weight of the composition, preferably between 0.08 and 3% by weight, preferably between 0.1 and 1% by weight. Preservatives and other additives The composition according to the invention may comprise at least one preservative and / or at least one additive. Preservatives include phenoxyethanol, caprylyl glycol, benzyl alcohol and mixtures thereof. Preferably, the composition according to the invention is substantially free of caprylyl glycol. By substantially free of caprylyl glycol, it is meant that the composition comprises less than 0.3% by weight, preferably less than 0.1% by weight relative to the total weight of the composition of caprylyl glycol. Preferably, the composition according to the invention is completely free of caprylyl glycol. Preferably, the composition according to the invention comprises at least phenoxyethanol. The additive can be any usual additive in the cosmetics field, such as for example a perfume or a filler. Preferably, the composition according to the invention comprises, in a cosmetically acceptable aqueous medium, by weight relative to the total weight of the composition: at least 55% by weight of water; magnesium chloride (MgCl) in a content of between 1 and 30% by weight relative to the total weight of the composition, preferably between 3 and 25% by weight, preferably between 5 and 20% by weight; dipotassium phosphate (K,HPO4) in a content of between 5 and 20%, preferably between 6 and 15% by weight, preferably between 7 and 12% by weight; between 0.05 and 5% by weight capryloyl salicylic acid, preferably between 0.08 and 3% by weight, preferably between 0.1 and 1% by weight; optionally at least one preservative, preferably phenoxyethanol; between 0.1 and 5% by weight of citric acid, preferably between 0.5 and 4% by weight, preferably between | and 3% by weight; between 0.05 and 5% by weight of sodium citrate, preferably between 0.1 and 3% by weight, preferably between 0.5 and 2% by weight; and between 0.5 and 4% by weight, preferably between 0.6 and 2% by weight, preferably between 0.7 and 1.5% by weight of xanthan gum. Application process The present invention also relates to a cosmetic process for treating human perspiration and possibly body odors resulting from the trans- piration (hereinafter “method according to the invention”), comprising the application of a composition according to the invention to the skin. The present invention finally relates to a cosmetic process for treating human perspiration and possibly body odors resulting from perspiration (hereinafter “process 2 according to the invention”), which comprises: (i) either the mixing just before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately followed by the application of the resulting mixture to the surface of the skin; (ii) either the application to the surface of the skin simultaneously or sequentially of at least one composition A and at least one composition B packaged separately; (iii) either the application to the surface of the skin of a composition comprising in the same support at least one composition A and at least one composition B; said composition comprising in a cosmetically ac- aqueous medium acceptable at least magnesium chloride (MgCl); said composition B comprising in a cosmetically ac- aqueous medium acceptable at least dipotassium phosphate (K,HPO;4); said composition A and / or said composition B comprising gum xanthan; said composition A and / or said composition B comprising acid capryloyl salicylic acid; and said composition A and / or said composition B also comprising at at least one modulating agent chosen from mono- or polycar- acids carboxylic, possibly hydroxylated, in free or salified form. To obtain an antiperspirant effect on the skin, according to a first variant of method 2 according to the invention (embodiment (i)), composition A and composition B are packaged separately and are mixed just before use (extemporaneous mixing) then the mixture thus obtained is applied to the surface of the skin to be treated. According to a second variant of method 2 according to the invention (embodiment (ii)), composition A and composition B are packaged separately and applied simultaneously or sequentially to the surface of the skin to be treated. According to this variant, when compositions A and B are applied sequentially, the time interval separating the application of composition A from application B can vary from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour. According to a third variant of method 2 according to the invention (embodiment (iii)), a composition comprising in the same support composition A and composition B. In this embodiment (iii), compositions A and B may for example be packaged in a device comprising at least two compartments respectively containing composition A and composition B such as a twin tube, a pump bottle with two compartments, an aerosol device comprising two compartments which may comprise one or more outlet orifices (single-nozzle or double-nozzle), a device provided with an openwork wall such as a grid comprising two compartments; a device comprising two compartments each provided with a roll-on applicator (multi-ball roll-on); a double-stick. Preferably, compositions A and B are applied sequentially and even more preferably, composition A (comprising at least magnesium chloride) is applied first. Preferably, the invention also relates to a method for the cosmetic treatment of human perspiration, and optionally of body odors linked to human perspiration, comprising the application to the surface of the skin, in particular to the surface of the armpits, an effective amount of composition A and an effective amount of composition B. The application time of composition A and / or B to the skin surface may vary from 0.5 to 10 seconds, preferably from 1 to 5 seconds. Compositions A and B may be applied several times to the skin surface. They may be applied several times, over one day or over several days. Preferably, the invention also relates to a method for the cosmetic treatment of human perspiration, and possibly body odors linked to human perspiration, comprising a first step of application to the surface of the skin, in particular to the surface of the armpits, of composition A, then a second step of application to the same surface, of composition B. DOSAGE FORMS The composition according to the invention can be presented in all the galenic forms conventionally used for topical application and in particular in the form of aqueous or hydroalcoholic gels, or in the form of aqueous sticks (i.e. solids). Preferably, it comes in the form of an aqueous gel or aqueous stick (i.e. solid). It can also, by adding a fatty or oily phase, be in the form of dispersions of the lotion type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or suspensions or emulsions of soft, semi-solid or solid consistency of the cream or gel type, or even multiple emulsions (W / O / W or O / W / O), microemulsions, vesicular dispersions of the ionic and / or non-ionic type, or wax / aqueous phase dispersions. These compositions are prepared according to standard methods. The composition may in particular be packaged in pressurized form in an aerosol device or in a pump bottle; packaged in a device equipped with a perforated wall, in particular a grid; packaged in a device equipped with a ball applicator (roll-on); packaged in the form of sticks, in the form of loose or compacted powder. In this respect, it contains the ingredients generally used in this type of product and well known to those skilled in the art. According to another particular form of the invention, the composition may be solid, in particular in the form of a stick; in the form of a loose or compacted powder. By "solid composition" is meant that the measurement of the maximum force measured by texturometry when a probe is inserted into the formula sample must be at least equal to 0.25 Newton, in particular at least equal to 0.30 Newton, in particular at least equal to 0.35 Newton, assessed under precise measurement conditions as follows: The formulas are poured hot into pots with a diameter of 4 cm and a base of 3 cm. Cooling is done at room temperature. The hardness of the formulas produced is measured after waiting for 24 hours. The pots containing the samples are characterized by texturometry using a texturometer such as the one marketed by Rhéo TA-XT2, according to the following protocol: a stainless steel ball probe with a diameter of 5 mm is brought into contact with the sample at a speed of 1 mm / s. The measuring system detects the interface with the sample with a detection threshold equal to 0.005 newtons. The probe sinks 0.3 mm into the sample, at a speed of 0.1 mm / s. The measuring device records the evolution of the force measured in compression over time, during the penetration phase. The hardness of the sample corresponds to the average of the maximum values ​​of the force detected during penetration, over at least 3 measurements. The composition may also include at least one deodorant active ingredient and / or at least one additional antiperspirant active ingredient. Examples of these additional deodorant active ingredients include bacteriostatic agents or bactericidal agents acting on the germs of axillary odors, such as 2,4,4"-trichloro-2"-hydroxydiphenyl ether (Triclosan), 2,4-dichloro-2"-hydroxydiphenyl ether, 3°,4',5'-trichlorosalicylanilide, 1-(3°,4'-dichlorophenyl)-3-(4'-chlorophenyl)urea (Triclocarban) or 3,7,11-trimethyldodeca-2,5,10-trienol (Farnesol); quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; polyols such as those of the glycerin type, 1,3-propanediol (ZEMEA PROPANEDIOL® marketed by Dupont Tate and Lyle Bioproducts), 1,2-decanediol (Symclariol® from the company Symrise); glycerin derivatives such as Caprylic / Capric Glycerides (CAPMUL MCM® from Abitec), Glycerol Caprylate or Caprate (DERMOSOFT GMCY® and DERMOSOFT GMC® respectively from STRAETMANS), Polyglyceryl-2 Caprate (DERMOSOFT DGMC® from STRAETMANS), biguanide derivatives such as polyhexamethylene biguanide salts; chlorhexidine and its salts; 4-Phenyl-4,4-dimethyl-2-butanol (SYMDEO MPP® from Symrise); cyclodextrins; or alum. The additional deodorant active ingredients may preferably be present in the compositions according to the invention in weight concentrations ranging from 0.01 to 10% by weight relative to the total weight of the composition. As an illustration of additional antiperspirant active agents, mention may in particular be made of antiperspirant salts or complexes of aluminum and / or zirconium, preferably chosen from aluminum halohydrates; aluminum and zirconium halohydrates, zirconium hydroxychloride and aluminum hydroxychloride complexes with or without an amino acid such as those described in patent US-3792068. Among the aluminum salts, mention may be made in particular of aluminum chlorohydrate in activated or non-activated form, aluminum chlorohydrex, aluminum chlorohydrex polyethylene glycol complex, aluminum chlorohydrex propylene glycol complex, aluminum dichlorohydrate, aluminum dichlorohydrex polyethylene glycol complex, aluminum dichlorohydrex propylene glycol complex, aluminum sesquichlorohydrate, aluminum sesquichlorohydrex polyethylene glycol complex, aluminum sesquichlorohydrex propylene glycol complex, aluminum sulfate buffered by sodium aluminum lactate. Among the aluminum and zirconium salts, we can cite in particular aluminum zirconium octachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium trichlorohydrate. Zirconium hydroxychloride and aluminum hydroxychloride complexes with an amino acid are generally known as ZAG (when the amino acid is glycine). These products include aluminum zirconium octachlorohydrex glycine, aluminum zirconium pentachlorohydrex glycine, aluminum zirconium tetrachlorohydrex glycine, and aluminum zirconium trichlorohydrex glycine. Aluminum sesquichlorohydrate is notably sold under the trade name REACH 301® by the company SUMMITREHEIS. Among the aluminum and zirconium salts, we can cite the complexes of zirconium hydroxychloride and aluminum hydroxychloride with an amino acid such as glycine having the INCI name: ALUMINUM ZIRCONIUM TETRA- CHLOROHYDREX GLY for example the one marketed under the name REACH AZP-908-SUF® by the company SUMMITREHEIS. More particularly, aluminium chlorohydrate in activated or unactivated form will be used, marketed under the trade names LOCRON S FLA®, LOCRON P, LOCRON L.ZA by the company CLARIANT; under the trade names MICRODRY ALUMINUM CHLOROHYDRATE®, MICRO-DRY 323®, CHLORHYDROL 50, REACH 103, REACH 501 by the company SUMMITREHEIS; under the trade name WESTCHLOR 200® by the company WESTWOOD; under the trade name ALOXICOLL PF 40® by the company GUILINI CHEMIE; CLURON 50%® by the company INDUSTRIA QUIMICA DEL CENTRO; CLOROHIDROXIDO ALUMINIO SO A 50%® by the company FINQUIMICA. Another antiperspirant active ingredient is expanded perlite particles such as those obtained by the expansion process described in US patent 5,002,698. Preferably, the composition comprises less than 5% by weight of aluminum salt, preferably less than 3% by weight, preferably less than 1% by weight. Preferably, it is completely free of aluminum salt. Throughout the description, including the claims, the expression "comprising a" should be understood as being synonymous with "comprising at least one", unless otherwise specified. The expressions “between … and …” and “ranging from … to .….” must be understood inclusively, unless otherwise specified. In the description and examples, unless otherwise indicated, percentages are by weight. Percentages are therefore expressed by weight relative to the total weight of composition (% w / w). Temperature is expressed in degrees Celsius unless otherwise indicated, and pressure is atmospheric pressure unless otherwise indicated. The invention is illustrated in more detail by the non-limiting examples presented below. Examples Example 1: Compositions The gel formulas below were prepared by mixing in water: Formulas CI and C2 are according to the invention, while formula CCI is comparative (no capryloyl salicylic acid). [Tables 1] LS 0.7 Qsp 100 | [8.6 5 LS 0.7 Qsp 100 8.6 |1o |1o [10 [Ingredient ci ci C2 (% w / w) (% Pw / w) (% Pw / w) Xanthan Gum 0.9 0.9 0.9 CAPRYLYL GLYCOL 0.5 0.5 PROPYLENE GLYCOL 5 5 Citric Acid js 15 L5 SODIUM CITRATE 07 07 07 |Water Qsp 100 Qsp 100 Qsp 100 Dipotassium Phosphate 8.6 8.6 8.6 (K,HPO,) Magnesium Chloride | 10 | 10 [io (MgCL) Capryloyl Salicylic Acid | Jo2 02 oz Caprylyl salicylic acid | ñ 02 0.2 Perfume 1.2 Phenoxyethanol 0.5 E Je 2 : Evaluation d Ç ibacterium The evaluation of the antimicrobial properties of formulas CCI, C1 and C2 of example 1 is carried out according to the following protocol: In summary, in a suitable culture medium, the biocidal effect of the formulas is evaluated on the strains of interest after 2h, 6h and 24h of contact in comparison with a placebo (i.e. medium without formula). At each contact time, the logarithmic reduction in the number of viable cells is measured. The model strain of "axillary odor" is: Corynebacterium freneyi CIP 52.16 (ex Corynebacterium xerosis) This strain is brought into contact with the formula to be tested in a culture medium in the following proportions: - 10% of the inoculum at 105 germs / ml, - 10% of the formula to be tested, and - 80% culture medium (Trypcase Soy broth). In parallel, a growth control, in which the formula is replaced by a diluent, is prepared under the same conditions. The samples are placed in an incubator at a temperature of 35°C (optimal growth temperature for the strain) with continuous agitation during the test. After 2, 6 and 24 hours of contact time, the number of viable microorganisms remaining in the mixture is evaluated. The results are expressed as the logarithm of the number of microorganisms per milliliter of mixture. The result obtained with the formula to be tested is compared to the results of the growth control and the difference is expressed as the number of Log difference at T 24 hours. The count (Log CFU / ml) for the 24-hour control is greater than 8 (approximately 8.5). The count (Log CFU / ml) for CCI at 24h is greater than 8 (approximately 8.3). The count (Log UFC / ml) for C1 at 24 hours is approximately 3.3. The count (Log UFC / ml) for C2 from 2 hours is approximately 2.3 (= detection threshold). Comparing the CCI formula and the CI formula, it appears that the antimicrobial activity of C1 is significantly improved by the addition of capryloyl salicylic acid (-4 Log at 24h). With the C2 formula according to the invention, all bacteria are killed in 2 hours. Formulas C1 and C2 according to the invention thus exhibit very good antimicrobial activity. Example 3: Compositions The gel formulas below were prepared by mixing in water: Formulas C3 to CS are according to the invention, while formulas CC2 to CC4 are comparative (no capryloy! salicylic acid). [Tables 2] q0 quo [Ingredient CC2 (% w / w) Xanthan gum 0.9 PROPYLENE GLYCOL Citric acid 1.5 SODIUMCITRATE 07 Water Qsp 100 Dipotassium phosphate (K 8.6 :HPO4) Magnesium chloride quo (MgCl:) Capryloyl salicylic acid Phenoxyethanol 05 Caprylyl salicylic acid 0.2 Phenoxyethanol 0.5 0.5 [Tables 3] [10 flo Ingredient CC3 (% w / w) Xanthan gum 0.9 Citric acid L5 SODIUM CITRATE 0.7 Water Qsp 100 Dipotassium phosphate (K |8.6 2HPO4) Magnesium chloride [10 (MgCl>) Capryloyl salicylic acid Fragrance 1,2 Phenoxyethanol! a 0.2 1.2 0.5 [Tables 4] |Ingredient CC4 (% w / w) 0.9 Xanthan gum CAPRYLYL GLYCOL Citric acid SODIUM CITRATE [En q0 quo Ja has Citric acid 15 SODIUM CITRATE 0.7 [Water Qsp 100 Dipotassium phosphate (K 8.6 2HPO;) Magnesium chloride quo (MgCl>) Capryloyl salicylic acid Perfume a Example 4: Evaluation of deodorant performance The evaluation of the deodorant properties of formulas CC2-CC4, and C3-C5 of example 3 is carried out according to the following protocol: METHODOLOGY Panel: 10 trained panelists for objective assessment. Performance verified for repeatability, discrimination, and consistency. Volunteers: 18 volunteers with underarms and strong underarm odor Application: 7 days of multi-application wash (4) Random product application Amount applied per day: 0.4g + 0.05 roll-on & stick 1.2 g + 0.05 aerosol Assessment: Intensity of bad odor, description of bad odor and intensity of fragrance. At TO, T4 and T24h after the 4th application. Sequential monadic. The results show the following values: [Tables 5] | Value TO T4h T24h The C3 formula according to the invention is significantly more effective than the comparative CC2 formula at 4h and 24h. [Tables 6] | Value TO T4h T24h The C4 formula according to the invention is slightly more effective than the comparative CC3 formula at 0 and 4h, but similar at 24h. [Tables 7] | Value (mo fre fran The C5 formula according to the invention is more effective than the comparative CC4 formula at 4 hours and 24 hours.

Claims

Claims

1. A composition comprising, in a cosmetically ac- aqueous medium acceptable, magnesium chloride, dipotassium phosphate, xanthan gum, capryloyl salicylic acid and at least one modulating agent chosen from mono- or polycarboxylic acids possibly hydroxylated, in free or salified form.

2. Composition according to claim 1, characterized in that it comprises magnesium chloride in a content of between | and 30% by weight relative to the total weight of the composition, preferably between 3 and 25% by weight, preferably between 5 and 20% by weight.

3. Composition according to claim 1 or 2, characterized in that it comprises dipotassium phosphate in a content of between 1 and 25% by weight relative to the total weight of composition, preferably between 3 and 20% by weight, preferably between 5 and 15% by weight.

4. Composition according to one of the preceding claims, characterized in what the weight ratio between magnesium chloride and dipotassium phosphate varies from 3:1 to 1:1, preferably from 2:1 to 1:1, and more preferably from 1.5:1 to 1:

1.

5. Composition according to one of the preceding claims, characterized in that the modulating agent is chosen from propionic acid, acid citric acid, tartaric acid, lactic acid, malic acid, acid succinic acid, glutaric acid, itaconic acid and mixtures thereof, in free or salified form.

6. Composition according to one of the preceding claims, characterized in that the modulating agent is a mixture of a tricarboxylic acid hydroxylated in free form and a hydroxylated tricarboxylic acid in salified form.

7. Composition according to one of the preceding claims, characterized in what the modulating agent is is a mixture of citric acid and citrate of sodium.

8. Composition according to one of the preceding claims, characterized in that the modulating agent is present in the composition in a content between 0.1 and 10% by weight relative to the total weight of com- position, preferably between 0.5 and 5% by weight, preferably between 1 and 4% by weight.

9. Composition according to one of the preceding claims, characterized in what xanthan gum is present in the composition in one content between 0.1 and 7% by weight relative to the total weight of composition, preferably between 0.5 and 5% by weight, preferably between 0.8 and 2% by weight.

10. | Composition according to one of the preceding claims, characterized in what capryloyl salicylic acid is present in the composition in a content of between 0.05 and 5% by weight relative to the total weight of composition, preferably between 0.08 and 3% by weight, preferably between 0.1 and 1% by weight.

11. Composition according to one of the preceding claims, characterized in which comprises at least 50% by weight of water relative to the weight total composition, preferably at least 55% by weight, of preferably at least 70% by weight; preferably, the composition comprises from 50% to 90% by weight of water relative to the total weight of composition, preferably from 55% to 85% by weight, preferably 55% to 80% by weight.

12. Composition according to one of the preceding claims, characterized in that it is substantially free of caprylyl glycol, preferably completely free of caprylyl glycol.

13. Composition according to one of the preceding claims, characterized in which it includes, in a cosmetically ac- aqueous medium acceptable, by weight relative to the total weight of composition: at least 55% by weight of water; magnesium chloride in a content of between 1 and 30% in weight relative to the total weight of composition, preferably between 3 and 25% by weight, preferably between 5 and 20% by weight; dipotassium phosphate in a content of between 5 and 20%, preferably between 6 and 15% by weight, preferably between 7 and 12% by weight ; between 0.05 and 5% by weight of caprylyl salicylic acid, preferably between 0.08 and 3% by weight, preferably between 0.1 and 1% by weight; possibly at least one preservative, preferably phe- noxyethanol; between 0.1 and 5% by weight of citric acid, preferably between 0.5 and 4% by weight, preferably between 1 and 3% by weight; between 0.05 and 5% by weight of sodium citrate, preferably between 0.1 and 3% by weight, preferably between 0.5 and 2% by weight; and between 0.5 and 4% by weight, preferably between 0.6 and 2% by weight, of preferably between 0.7 and 1.5% by weight of xanthan gum.

14. Cosmetic process for treating human perspiration and possibly actually body odor resulting from perspiration, comprising the application of a composition according to one of the re- previous instructions on the skin.

15. Cosmetic process for treating human perspiration and possibly actually body odor resulting from perspiration, which understand : {i) either the mixing just before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately followed by application of the mixture resulting on the surface of the skin; (ii) either the application to the skin surface simultaneously or sequential of at least one composition A and at least one com- position B packaged separately; (iii) the application to the surface of the skin of a composition comprising in the same support at least one composition A and at less one composition B; said composition comprising in an aqueous medium cos- metrically acceptable at least magnesium chloride; said composition B comprising in an aqueous medium cos- metrically acceptable at least di-phosphate potassium; said composition A and / or said composition B comprising xanthan gum; said composition A and / or said composition B comprising caprylyl salicylic acid; and said composition A and / or said composition B comprising also at least one modulating agent chosen from mono- or polycarboxylic acids possibly hy- droxylated, in free or salified form.